VV-gp100

VV-gp100 is an investigational recombinant viral vector vaccine designed for the treatment of metastatic melanoma. It utilizes a modified vaccinia virus as a vector to deliver the gene encoding the melanoma-associated antigen gp100 (also known as PMEL). Upon administration, the virus infects host cells, leading to the expression and presentation of the gp100 protein, which subsequently triggers a robust, antigen-specific T-cell mediated immune response against melanoma cells. This therapeutic approach aims to overcome immune tolerance to self-antigens expressed by tumors. VV-gp100 has been extensively studied by the National Cancer Institute (NCI), often in heterologous prime-boost regimens or in combination with systemic cytokines such as Interleukin-2 (IL-2) to enhance the proliferation and anti-tumor activity of the induced T-cells.

Other names

Recombinant vaccinia virus-gp100Vaccinia-gp100Vaccinia-gp-100Vaccinia-gp 100rVV-hgp100rVV-hgp-100rVV-hgp 100